The consortium is collecting data from different omics streams for a cohort of individuals with autism spectrum disorders with the long-term goal of improving treatment.
Investigators intend to genotype the biorepository using Illumina arrays with the aim of identifying markers that can be used to inform treatment and prevention efforts.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
The researchers will use single-cell genomics and other approaches to generate information that could ultimately be used to diagnose, monitor, and treat disease.
The Finnish bioinformatics firm will aid European researchers and animal-focused diagnostics companies in developing a functional annotation of the dog genome.
The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
The consortium is made up of Genome Profiling, Rob Knight's UCSD lab, KromaTid, Metabolon, and Orig3n, and is sponsored by a new company called Interome.
